Managing The Expansion of Clinical Trial Data Sources

Increases in remote patient monitoring and decentralized clinical trials – accelerated by COVID-19 – have added complexity to data management systems. Traditional platforms and electronic data capture used by drug development sponsors are ineffectual tools for integrating new primary data sources, or managing remote patient monitoring, Raj Indupuri, CEO at eClinical Solutions told In Vivo. 

Big data concept. 3D .Thousands bar graphs forming words big data
• Source: Shutterstock

Recently, many of the largest biopharmaceutical companies worldwide have gotten interested in modernizing their technology infrastructures and data management processes for clinical research, said Raj Indupuri, CEO at eClinical Solutions, a provider of cloud-based software for clinical data services. The practical realities of operating during COVID-19, as well as pressure from governments and patients, are prompting a reconsideration of technology needs. Remote patient monitoring has become critical to clinical research, as well as the need to integrate an ever-growing number of primary data sources into data management systems for analysis.

The problem with data management systems, said Indupuri, is that the increase in data sources “disrupts the traditional data review...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

How Rapport Transferred A Decade Of Big Pharma Neuroscience Expertise To Biotech

 
• By 

Rapport Therapeutics CEO discusses the company's novel approach to AMPA modulation and why strategic externalization from J&J is accelerating neuroscience innovation.

Podcast: Merck’s Vision For Making Digital Health Redundant

 
• By 

Merck KGaA's Emre Ozcan outlines the company's systematic approach to integrating digital solutions across the care continuum in specialty pharmaceuticals, moving from technology-first to patient-need-first strategies.

Does ReproNovo’s $65m Raise Signal An Oasis In The Fertility Investment Desert?

 
• By 

ReproNovo's $65m Series A targets the $1.5bn male infertility market with the first potential oral therapy. Its first-in-class approach to underserved conditions like adenomyosis positions it as an attractive acquisition target in fertility's concentrated market.

Moderna Veteran Launches Icelandic mRNA Firm Despite US Retreat

 
• By 

Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.

More from In Vivo

Podcast: Tevard CEO Sees Hope For His Daughter In Company’s tRNA Platform

 
• By 

Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs overcome nonsense mutations, restoring full-length protein production to treat rare genetic diseases like Dravet syndrome.

Deals In Depth: July 2025

 
• By 

Six $1bn+ alliances were penned in July, and two exceeded $2bn.

Execs On The Move: July 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.